Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of a Single Infusion of Zoledronic Acid to Mitigate the Rebound Effect of Rapid Bone Loss Following Denosumab Treatment Discontinuation

NCT05405894 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT05405894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of a Single Infusion of Zoledronic Acid to Mitigate the Rebound Effect of Rapid Bone Loss Following Denosumab Treatment Discontinuation
Lead sponsor
University of Calgary
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2022
Completion date
July 1, 2025
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone loss, osteopenia, osteoporosis, osteoporosis, postmenopausal